MicroRNA223 promotes pathogenic T-cell development and autoimmune inflammation in central nervous system in mice

Tiffany Satoorian1, Bo Li2, Xiaolei Tang2

  • 1J.L. Pettis VA Medical Center, Loma Linda, CA, USA.

Immunology
|April 17, 2016
PubMed

Insights

MicroRNA 223 promotes multiple sclerosis (MS) development by enhancing dendritic cell activation and T cell differentiation. Knocking out miR223 in mice delayed disease onset and reduced symptoms in an MS model.

Area of Science:

  • Neuroimmunology
  • Molecular Biology
  • Immunology

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system.
  • Understanding MS pathogenesis is crucial for developing effective therapies.
  • Experimental autoimmune encephalomyelitis (EAE) serves as a key animal model for MS research.

Purpose of the Study:

  • To identify novel microRNAs regulating experimental autoimmune encephalomyelitis (EAE).
  • To investigate the role of microRNA 223 (miR223) in MS pathogenesis.
  • To elucidate the mechanisms by which miR223 influences immune cell function in EAE.

Main Methods:

  • Generated global miR223 knockout mice (miR223(-/-)) and used bone marrow chimeras.
  • Analyzed EAE onset, spinal cord lesions, and neurological symptoms.
  • Assessed immune cell infiltration (Th1, Th17) and gene expression in spleen and spinal cord.
  • Investigated dendritic cell (DC) activation markers (CD86, MHC II) and cytokine production (IL-12, IL-23).

Main Results:

  • miR223 expression was specifically upregulated in spinal cords and lymphoid organs during EAE.
  • miR223(-/-) mice exhibited delayed EAE onset, reduced spinal cord lesions, and milder neurological symptoms.
  • Deficiency in miR223 reduced Th1 and Th17 cell infiltration into the spinal cords.
  • miR223 deficiency decreased DC activation and IL-12/IL-23 production, impairing Th1/Th17 differentiation.

Conclusions:

  • miR223 plays a pro-inflammatory role in EAE pathogenesis.
  • miR223 promotes EAE by enhancing dendritic cell activation and subsequent Th1/Th17 cell differentiation.
  • Targeting miR223 may offer a therapeutic strategy for multiple sclerosis.